• Home
  • Journal
  • Public Companies
  • BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

BioNexus Gene Lab Corp. Signs Strategic Partnership MOU with Shenzhen Rongguang Group to Advance Cancer Screening, Precision Medicine, and Preventative Healthcare Solutions

Written by Customer Service on . Posted in Public Companies.

BGLC CEO and representative of Shenzhen Rongguang Health MOU Signing Ceremony

BGLC CEO and representative of Shenzhen Rongguang Health MOU Signing Ceremony
BGLC CEO and representative of Shenzhen Rongguang Health MOU Signing Ceremony

KUALA LUMPUR, Malaysia, Sept. 13, 2024 (GLOBE NEWSWIRE) — BioNexus Gene Lab Corp. (Nasdaq: BGLC, the “Company”), an emerging biotechnology company focused on innovative healthcare solutions, is pleased to announce the signing of a strategic partnership Memorandum of Understanding (MOU) with Shenzhen Rongguang Health Group, a major healthcare services provider in China. This partnership aims to expand the Company’s expertise and presence in cancer screening, precision medicine, and preventative healthcare through its subsidiary MRNA Scientific Sdn Bhd.

The partnership between the Company and Shenzhen Rongguang Health Group represents a significant step forward in developing advanced healthcare technologies, with a focus on early cancer detection, personalized healthcare solutions, and broader preventative care. By combining the strengths of the Company’s proprietary molecular diagnostics and Shenzhen Rongguang Health Group’s healthcare infrastructure, the collaboration will drive innovations in early detection, regenerative medicine, and chronic disease management.

Key Objectives of the Partnership

The strategic partnership will allow both companies to leverage their expertise to address critical healthcare challenges and improve patient outcomes. The primary goals include:

  1. Expansion of Cancer Screening and Diagnostics: MRNA Scientific Sdn Bhd, a subsidiary of BGLC, will lead efforts to enhance cancer screening capabilities across Southeast Asia and China. By introducing advanced genomic testing and molecular diagnostics, the partnership will enable earlier detection of cancers and other diseases, improving survival rates and treatment effectiveness.
  2. Research and Development in Regenerative Medicine: Both companies will collaborate on research and development in advanced healthcare technologies, including non-cellular exosome therapy and regenerative medicine. These cutting-edge treatments offer new possibilities for anti-aging therapies, chronic disease management, and personalized health solutions, extending beyond cancer detection into broader healthcare innovations.
  3. Preventative Healthcare and Chronic Disease Management: The partnership will explore opportunities to improve preventative healthcare services, focusing on managing chronic conditions, enhancing patient quality of life, and offering personalized healthcare plans based on advanced diagnostics. This aligns with the global trend toward precision medicine and healthcare that is tailored to individual genomic profiles and risk factors.
  4. Synergy in Technological Innovation: The collaboration will combine the Company’s diagnostic capabilities with Shenzhen Rongguang Health Group’s established healthcare platforms to create synergies in healthcare innovation. This will allow both companies to introduce new healthcare technologies that improve the detection, prevention, and treatment of various diseases, while expanding access to these solutions in underserved markets.

Sam Tan, CEO of BioNexus Gene Lab Corp, stated:
“This partnership marks a pivotal moment for BGLC and our subsidiary, MRNA Scientific Sdn Bhd. By joining forces with Shenzhen Rongguang Health Group, we are not only advancing our efforts in cancer screening but also expanding into the broader healthcare sector with cutting-edge solutions for preventative medicine and regenerative healthcare. This will enable us to deliver superior healthcare outcomes for patients across Asia.”

About BioNexus Gene Lab Corp.

BioNexus Gene Lab Corp. (BGLC) is an emerging biotechnology company focused on providing innovative solutions in healthcare. BGLC is committed to advancing precision medicine, early diagnostics, and cutting-edge therapies to improve patient care and outcomes.

For more information, please visit www.bionexusgenelab.com.

Contact Information:

Investor Relations
BioNexus Gene Lab Corp
Email: ir@bionexusgenelab.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/4f640e01-d514-4a61-8b9a-292e8cd58d47

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.